TheraRadar
Data updated: May 26, 2026

CABENUVA KIT (cabotegravir)

Priority Review Fast Track
Infectious Disease Approved 2021-01-21

CABENUVA KIT is indicated for the treatment of HIV-1 Infection.

Source: FDA Label • VIIV HLTHCARE
6
Indications
--
Phase 3 Trials
3
Priority Reviews
5
Years on Market

Details

Status
Prescription
First Approved
2021-01-21
Patent Cliff
2038

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAMUSCULAR
Dosage Forms
SUSPENSION, EXTENDED RELEASE

Companies

Active Ingredient: CABOTEGRAVIR , RILPIVIRINE

CABENUVA KIT Approval History

2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
22 FDA actions from 2021 to 2025 · 5 indication expansions
Nov 2025 SUPPL
Label · Labeling
Apr 2025 SUPPL
Label · Labeling
Sep 2024 SUPPL Priority
Efficacy

What CABENUVA KIT Treats

1 indications

CABENUVA KIT is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • HIV-1 Infection
Source: FDA Label

CABENUVA KIT Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CABENUVA KIT

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ABACAVIR SULFATE
ABACAVIR SULFATE
1 shared
Aurobindo Pharma
Shared indications:
APRETUDE
CABOTEGRAVIR
1 shared
VIIV HLTHCARE
Shared indications:
APTIVUS
TIPRANAVIR
1 shared
Boehringer Ingelheim
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT05996471 EMBRACE 209639 Ph 2 active not recruiting A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT03149848 results posted 205712 2017-000103-25 Ph 1 completed Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
NCT02462772 CAPRISA014 CAPRISA 014 Ph 2 withdrawn Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CABENUVA KIT FDA Label Details

Indications & Usage

FDA Label (PDF)

CABENUVA KIT is indicated for the treatment of HIV-1 Infection.

View full patent landscape →
8 OB patents · 6 families · 396 international docs across 46 countries

CABENUVA KIT Patents & Exclusivity

Latest Patent: Jul 2038
Exclusivity: Jan 2026

Patents (8 active)

US12178815 Expires Jul 18, 2038
US11389448 Expires Apr 13, 2032
USRE50189 Expires Nov 27, 2031
US12138264 Expires Sep 15, 2031
US11224597 Expires Sep 15, 2031
US8410103 Expires Feb 4, 2031
US11389447 Expires Jun 30, 2027
US10927129 Expires Apr 28, 2026

Exclusivity

NCE Until Jan 2026
NCE Until Jan 2026
NCE Until Jan 2026
NCE Until Jan 2026
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for CABENUVA KIT

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2038
  • 32 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.